79 articles
Robinhood data reveals a preference for growth stocks, but analysts warn of overvaluation and regulatory challenges. Investors are also exploring speculative bets and durable blue chips.
Robinhood data reveals a preference for growth stocks, but some investors are diversifying into blue chips and speculative plays. Analysts warn of overvaluation and regulatory risks.
Bitcoin has filled a closely watched $88,000 CME futures gap following President Trump's speech at Davos, where he reaffirmed plans to make the United States the 'crypto capital of the world.' Traders view the technical milestone as a potential reset rather than reversal, with the market now watching whether policy optimism can translate into sustained buying pressure.
Meta's ambitious spending plans have led to a market backlash, while Amazon's recent success hints at continued dominance. Meanwhile, PayPal's undervalued stock presents an intriguing opportunity.
President Trump's ruling out of military action to annex Greenland has bolstered market confidence, but analysts warn that geopolitical tensions could resurface. The Dow surged following the announcement at the World Economic Forum in Davos.
While the consumer staples sector struggled in 2025, Coca-Cola outperformed Procter & Gamble. Both stocks could offer solid value in the coming year.
While the consumer staples sector struggled in 2025, Coca-Cola outperformed Procter & Gamble. Both companies present intriguing investment opportunities in the coming year.
Zacks Market Edge, hosted by Tracey Ryniec, delves into the latest investing trends in stocks, bonds, and ETFs. This week, discussions revolve around the 'Magnificent 7', high-growth sectors, and potential market corrections.
Alphabet and Microsoft are making significant strides in quantum computing with new processors and algorithms, driving hopes for industry breakthroughs. However, high investment costs and uncertain timelines pose risks.
The public feud between Elon Musk and Ryanair CEO Michael O'Leary has sparked interest in prediction markets, with bets on potential outcomes like a SpaceX takeover. However, the conflict could also lead to reputational risks for both parties.
Thiel Macro has divested from Nvidia but maintains a strong position in Tesla. The fund sees Microsoft as a lower-risk investment with significant growth potential, highlighting the evolving landscape of tech investments.
Apple and Microsoft continue to dominate, but analysts warn of intense competition and reliance on key products. Meanwhile, Nvidia benefits from rising AI adoption.
Friday saw Wall Street end with marginal losses, reflecting ongoing market uncertainty. Analysts highlight both promising developments in AI and biotech partnerships, as well as potential regulatory challenges.
UnitedHealth faces significant headwinds, including a 34% stock decline, but analysts see potential for recovery through improved billing practices and sustainable growth strategies.
US stock futures remain stagnant ahead of major bank earnings and a potential Supreme Court decision on US tariffs, with market outcomes hinging on these events.
US stock futures declined Wednesday morning, reflecting a pullback from recent record highs. Analysts weigh potential impacts of upcoming bank earnings and geopolitical uncertainties on market sentiment.
The Supreme Court is set to rule on Trump-era tariffs, potentially lifting a weight off certain stocks but introducing new uncertainties. Analysts see both opportunities and risks ahead.
The BBC has outlined its defense against President Trump's defamation lawsuit, arguing the documentary was fair. This case could have significant implications for media freedom and the corporation's financial stability.
AbbVie has agreed to a three-year deal with the Trump administration to reduce drug prices and invest $100 billion in U.S. R&D and manufacturing. This move could enhance patient access but raises concerns about long-term financial sustainability and innovation.
Guardant Health reported a 39% year-over-year increase in Q4 revenue, driven by robust oncology and screening volumes. However, intense competition and financial challenges pose risks to its future growth.